Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:42 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 50,388 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Clear all
Completed Phase 1 Interventional

Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00004079
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
SarCNU, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Nov 3, 2026, 8:42 AM EST
Active, not recruiting No phase listed Observational

Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases

NCT07485179
View directory record Official record
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Initiation of pembrolizumab, Initiation of chemotherapy
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

NCT03932279
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Enrolling by invitation Phase 1Phase 2 Interventional

Anti-viral T-cell Therapy by Gamma Capture

NCT06027879
View directory record Official record
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions
Specific T- Lymphocytes
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
1 Month to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Completed Not applicable Interventional

Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer

NCT00900679
View directory record Official record
Conditions
Ovarian Cancer, Transitional Care Planning
Interventions
telephone-based intervention, counseling intervention, educational intervention, medical chart review, questionnaire administration, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 2 Interventional

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00677079
View directory record Official record
Conditions
Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer
Interventions
Iniparib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Nov 3, 2026, 8:42 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Rural Adult and Youth Sun Protection Study

NCT06439979
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer
Interventions
RAYS Intervention
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
3 Years to 7 Years
Enrollment
843 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
2
States / cities
Salt Lake City, Utah • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Completed Not applicable Interventional Results available

Stepped-Care Telehealth for Distress in Cancer Survivors

NCT03060096
View directory record Official record
Conditions
Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer
Interventions
Severe Anxiety/depression: High Intensity Stepped Care, Moderate Anxiety/depression: Low Intensity Stepped care, Enhanced Usual Care Control
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
166
States / cities
Fort Smith, Arkansas • Fresno, California • Modesto, California + 129 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Completed No phase listed Observational

Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer

NCT03746262
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Nov 3, 2026, 8:42 AM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

NCT04653246
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Interventions
Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone
Drug
Lead sponsor
Jacob Laubach, MD
Other
Eligibility
75 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 1 Interventional

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

NCT05178888
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
MRTX849, Palbociclib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Orlando, Florida • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Nov 3, 2026, 8:42 AM EST
Completed No phase listed Observational

Breast Cancer Molecular Analysis Protocol

NCT01855503
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Core Biopsy
Procedure
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 1 Interventional

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

NCT01317927
View directory record Official record
Conditions
Solid Tumor, Hematological Malignancy
Interventions
Belinostat, Warfarin
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 2 Interventional Results available

Low Dose Radiation Therapy for Glioblastoma Multiforme

NCT01466686
View directory record Official record
Conditions
High Grade Glioma
Interventions
Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 3, 2026, 8:42 AM EST
Completed Early Phase 1 Interventional Results available

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

NCT01275586
View directory record Official record
Conditions
Neurofibromatosis, NF1, Neurofibromas
Interventions
Tasigna
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 2 Interventional

Rapid Easy Strength Training (REST) to Improve Function in Late Stage Cancer

NCT01334983
View directory record Official record
Conditions
Cancer
Interventions
REST
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 4 Interventional

Non-small Cell Lung Cancer Registry

NCT00099541
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
101
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Anaheim, California + 93 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Nov 3, 2026, 8:42 AM EST
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016
View directory record Official record
Conditions
Relapsed/Refractory Small Cell Lung Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Completed Not applicable Interventional

Lung Cancer Information Study (LCIS-R01)

NCT01924416
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Enhanced Care (intervention group and comparison group), Usual care (routine chemotherapy cycles and imaging studies)
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

NCT00086216
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Atiprimod
Drug
Lead sponsor
Callisto Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 1 Interventional

Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation

NCT00428233
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Leukemia cell harvest
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Nov 3, 2026, 8:42 AM EST
Terminated Phase 2 Interventional Results available

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

NCT01507545
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colorectal Cancer
Interventions
MORAb-004, Placebo, Best supportive care
Drug · Other
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Alhambra, California • Bakersfield, California • Burbank, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 1 Interventional

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

NCT00644072
View directory record Official record
Conditions
Lymphoma, Neoplasms
Interventions
SNX-5422
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 3, 2026, 8:42 AM EST
Recruiting Phase 2 Interventional

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

NCT02115295
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis, Midostaurin, Venetoclax
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 3, 2026, 8:42 AM EST